PSORIASIS AND ITS MANAGEMENT

1 Lomholt G. Psoriasis: Prevalence, spontaneous course and genetics. Copenhagen: GEC GAD; 1963.

2Van de Kerkhof PCM. Textbook of Psoriasis. Oxford: Blackwell; 1999.

3 McCormick A D Fleming Charlton J. Morbidity statistics from general practice: fourth national survey1991–92. London: OPCS; 1996.

4 Grob JJ. Psoriasis. In: Grob JJ, Stern RS, MacKie RM eds. Epidemiology, causes and prevention of skin diseases. Oxford: Blackwell Science; 1997; 203–26.

5 Grob JJ Folchetti G. Epidemiology. In: Van de Kerkhof PCM, ed. Textbook of Psoriasis. Oxford: Blackwell; 1999; 57–67.

6 Nevitt GJ Hutchinson PE. Psoriasis in the community: prevalence, severity and patients’ beliefs and attitudes towards the disease. Br J Dermatol 1996; 135(4):533–7.

7 Henseler T Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13(3):450–6.

8 Traupe H. The complex genetics. In: Van de Kerkhof PCM, ed. Textbook of Psoriasis. Oxford: Blackwell; 1999; 68–78.

9 Brandrup F N Holm Grunnet N Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol (Stockh) 1982; 62(3):229–36.

10 Duffy DL LS Spelman Martin NG. Psoriasis in Australian twins. J Am Acad Dermatol 1993; 29(3):428–34.

11 Swanbeck G A Inerot Martinsson T Genetic counselling in psoriasis: empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands. Br J Dermatol 1997; 137(6):939–42.

12 Telfer NR RJG Chalmers Whale K The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992; 128:39–42.

13 Tschachler E PR Bergstresser Stingl G. HIV-related skin diseases. Lancet 1996; 348(9028):659–63.

14 Litt JZ. Drug Eruption Reference Manual. New York and London: Parthenon Publishing Group; 1999.

15 Naldi L L Peli Parazzini F (Psoriasis Study Group Italian Grp Ep). Association of early-stage psoriasis with smoking and male alcohol consumption – evidence from an Italian case-control study. Arch Dermatol 1999; 135(12):1479–84.

16 O’Doherty CJ MacIntyre C. Palmoplantar pustulosis and smoking. BMJ 1985; 291(6499):861–4.

17 Williams HC. Smoking and psoriasis [editorial]. BMJ 1994; 308(6926):428–9.

18 Shuster S. Stress and psoriasis [letter]. Br J Dermatol 1979; 100(5):614–16.

19 Barker J. Psoriasis. J R Coll Physicians Lond 1997; 31(3):238–40.

20 Griffiths CE. Immunotherapy for psoriasis: from serendipity to selectivity. Lancet 2002; 359(9303):279–80.

21 Finlay AY. Psoriasis from the patient’s point of view. Arch Dermatol 2001; 137(3):352–3.

22 Ingram JT. The approach to psoriasis. BMJ 1953; 2:591–4.

23Al Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000; 42(5):796–802.

24 Lebwohl M Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001; 45(5):649–61.

25 Gerritsen MJP. Dithranol. In: Van de Kerkhof PCM, ed. Oxford: Blackwell; 1999; 160–78.

26 Rogers S J Marks Shuster S Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis. Lancet 1979; 1(8114):455–8.

27 Kragballe K BT Gjertsen De Hoop D Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris [published erratum appears in Lancet 1991;337(8747):988] [see comments]. Lancet 1991; 337(8735):193–6.

28 Parrish JA TB Fitzpatrick Tanenbaum L Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 1974; 291(23):1207–11.

29 Gordon PM BL Diffey Matthews JNS A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999; 41(5):728–32.

30 Stern RS EJ Liebman Väkevä L Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. J Natl Cancer Inst 1998; 90(17):1278–84.

31 Wolff K. Should PUVA be abandoned? N Engl J Med 1997; 336(15):1090–1. Also: Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med 1997; 336:1041–5.

32 Parrish JA Jaenicke KF. Action spectrum for phototherapy of psoriasis. J Invest Dermatol 1981; 76(5):359–62.

33 Van Weelden H De la Faille HB Young E A new development in UVB phototherapy of psoriasis. Br J Dermatol 1988; 119:11–19.

34 Boffa MJ Methotrexate Chalmers RJ. for psoriasis. Clin Exp Drmatol 1996; 21:399–408.

35 Mihatsch MJ Wolff K. Consensus conference on cyclosporin A for psoriasis. Br J Dermatol 1992; 126(6):621–3.

36 Kirby B Griffiths CE. Novel immune-based therapies for psoriasis. Br J Dermatol 2002; 146(4):546–51.

37 Singri P DP West Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002; 138(5):657–63.

38 Markham T S Rogers Collins O. Narrowband UB-B (TL-01) phototherapyvs oral 8-Methoxypsoralen psoralen- UV-A for the treatment for the treatment of chronic plaque psoriasis. Arch Dermatol 2003; 139:325–8.

39 Rees J. Complex disease and the new clinical sciences. Science 2002; 296:698–700.